Literature DB >> 8200964

Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.

T Laitala1, H K Väänänen.   

Abstract

The bone resorbing cells, osteoclasts, express high levels of carbonic anhydrase II (CA II) and vacuolar H(+)-ATPase (V-ATPase) during bone resorption. We have used antisense RNA and DNA molecules targeted against CA II, and against 16- and 60-kD subunits of vacuolar H(+)-ATPase (V-ATPase), to block the expression of these proteins in vitro. Osteoclastic bone resorption was studied in two in vitro culture systems: release of 45Calcium from prelabeled newborn mouse calvaria cultures, and resorption pit assays performed with rat osteoclasts cultured on bovine bone slices. Both antisense RNA and DNA against CA II and the V-ATPase were used to compare their specificities as regards inhibiting bone resorption in vitro. The antisense molecules inhibited the synthesis of these proteins by decreasing the amounts of mRNA in the cells in a highly specific manner. In osteoclast cultures treated with the 16-kD V-ATPase antisense RNA, acidification of an unknown population of intracellular vesicles was highly stimulated. The acidification of these vesicles was not sensitive to amiloride or bafilomycin A1. This suggests the existence of a back-up system for acidification of intracellular vesicles, when the expression of the V-ATPase is blocked. Our results further indicate that blocking the expression of CA II and V-ATPase with antisense RNA or DNA leads to decreased bone resorption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200964      PMCID: PMC294435          DOI: 10.1172/JCI117235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo.

Authors:  M Simons; E R Edelman; J L DeKeyser; R Langer; R D Rosenberg
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

2.  Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.

Authors:  G Y Wu; C H Wu
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

3.  RNase H-mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity.

Authors:  B Larrouy; C Blonski; C Boiziau; M Stuer; S Moreau; D Shire; J J Toulmé
Journal:  Gene       Date:  1992-11-16       Impact factor: 3.688

4.  Antisense probes targeted to an internal domain in U2 snRNP specifically inhibit the second step of pre-mRNA splicing.

Authors:  S M Barabino; B S Sproat; A I Lamond
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

5.  Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes.

Authors:  H Y Wang; D C Watkins; C C Malbon
Journal:  Nature       Date:  1992-07-23       Impact factor: 49.962

6.  Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18.

Authors:  C Steele; P G Sacks; K Adler-Storthz; E J Shillitoe
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

7.  The use of antisense mRNA to inhibit the tonoplast H+ ATPase in carrot.

Authors:  J P Gogarten; J Fichmann; Y Braun; L Morgan; P Styles; S L Taiz; K DeLapp; L Taiz
Journal:  Plant Cell       Date:  1992-07       Impact factor: 11.277

8.  Anti-sense transforming growth factor alpha oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line.

Authors:  A M Sizeland; A W Burgess
Journal:  Mol Biol Cell       Date:  1992-11       Impact factor: 4.138

9.  Proton channel part of vacuolar H(+)-ATPase and carbonic anhydrase II expression is stimulated in resorbing osteoclasts.

Authors:  T Laitala; K Väänänen
Journal:  J Bone Miner Res       Date:  1993-01       Impact factor: 6.741

10.  Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene.

Authors:  M C Pepin; F Pothier; N Barden
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

View more
  16 in total

Review 1.  Molecular aspects of osteoclast function.

Authors:  T J Hall; T J Chambers
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

2.  Resorption-cycle-dependent polarization of mRNAs for different subunits of V-ATPase in bone-resorbing osteoclasts.

Authors:  T Laitala-Leinonen; M L Howell; G E Dean; H K Väänänen
Journal:  Mol Biol Cell       Date:  1996-01       Impact factor: 4.138

3.  Quantitative Trait Locus and Integrative Genomics Revealed Candidate Modifier Genes for Ectopic Mineralization in Mouse Models of Pseudoxanthoma Elasticum.

Authors:  Qiaoli Li; Vivek M Philip; Timothy M Stearns; Jason A Bubier; Benjamin L King; Benjamin E Low; Michael V Wiles; Amir Hossein Saeidian; Beth A Sundberg; Jouni Uitto; John P Sundberg
Journal:  J Invest Dermatol       Date:  2019-06-15       Impact factor: 8.551

4.  A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Authors:  L Visentin; R A Dodds; M Valente; P Misiano; J N Bradbeer; S Oneta; X Liang; M Gowen; C Farina
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 5.  Spatial regulation of controlled bioactive factor delivery for bone tissue engineering.

Authors:  Julia E Samorezov; Eben Alsberg
Journal:  Adv Drug Deliv Rev       Date:  2014-11-29       Impact factor: 15.470

6.  Proteomic analysis of osteoclast lipid rafts: the role of the integrity of lipid rafts on V-ATPase activity in osteoclasts.

Authors:  Jiyoon Ryu; Hyunsoo Kim; Eun-Ju Chang; Hyung Joon Kim; Youngkyun Lee; Hong-Hee Kim
Journal:  J Bone Miner Metab       Date:  2010-02-02       Impact factor: 2.626

7.  Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.

Authors:  Z Zimolo; G Wesolowski; G A Rodan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 8.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

9.  A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.

Authors:  Kazuaki Niikura; Mikiko Takano; Masae Sawada
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

10.  Distinctive subdomains in the resorbing surface of osteoclasts.

Authors:  Kinga A Szewczyk; Karen Fuller; Tim J Chambers
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.